{
    "ticker": "TRIB",
    "name": "Tricida, Inc.",
    "description": "Tricida, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for patients with chronic kidney disease (CKD). Founded in 2013, Tricida is committed to addressing the unmet medical needs of patients suffering from the complications of CKD, particularly through its lead product candidate, veverimer. Veverimer is an investigational drug designed to bind to and remove excess acid from the gastrointestinal tract, thereby helping to manage metabolic acidosis, a common condition in CKD patients. The company's mission is to improve kidney health and enhance the quality of life for patients by providing effective treatment options. Tricida is dedicated to conducting rigorous clinical trials and collaborating with healthcare professionals to ensure that its therapies are safe and effective. With a strong pipeline and a focus on research and development, Tricida aims to become a leader in the field of nephrology, delivering solutions that can change the standard of care for CKD patients.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2013",
    "website": "https://www.tricida.com",
    "ceo": "Glen A. Mathews",
    "social_media": {
        "twitter": "https://twitter.com/TricidaInc",
        "linkedin": "https://www.linkedin.com/company/tricida/"
    },
    "investor_relations": "https://investors.tricida.com",
    "key_executives": [
        {
            "name": "Glen A. Mathews",
            "position": "CEO"
        },
        {
            "name": "Peter M. D. H. Heffernan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Veverimer"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tricida, Inc. | Innovative Therapeutics for Chronic Kidney Disease",
        "meta_description": "Explore Tricida, Inc., a biopharmaceutical company focused on developing therapies for chronic kidney disease. Learn about their lead product, veverimer, and their commitment to improving kidney health.",
        "keywords": [
            "Tricida",
            "Chronic Kidney Disease",
            "Biopharmaceuticals",
            "Veverimer",
            "Nephrology",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What does Tricida focus on?",
            "answer": "Tricida focuses on developing therapeutics for patients with chronic kidney disease."
        },
        {
            "question": "What is veverimer?",
            "answer": "Veverimer is an investigational drug designed to manage metabolic acidosis in chronic kidney disease patients."
        },
        {
            "question": "Where is Tricida headquartered?",
            "answer": "Tricida is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "When was Tricida founded?",
            "answer": "Tricida was founded in 2013."
        }
    ],
    "competitors": [
        "AKRO",
        "SNY",
        "AMGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "BMY",
        "JNJ"
    ]
}